fulranumab

{{Short description|Chemical compound}}

{{Use dmy dates|date=June 2019}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458274903

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = NGF

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 902141-80-4

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 0E986JU40I

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6446 | H=9930 | N=1718 | O=2018 | S=50

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D09907

}}

Fulranumab is a monoclonal antibody against nerve growth factor.{{cite web | vauthors = Verburg K | date = 12 March 2012 | url = https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm301305.pdf | archive-url = https://web.archive.org/web/20161020120107/https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm301305.pdf | archive-date = 20 October 2016 | title = Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain | work = Medicines Development Group, Pfizer Inc., Arthritis Advisory Committee Meeting | publisher = U.S. Food and Drug Administration }} It was designed for the treatment of pain.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab |publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf | archive-url = https://web.archive.org/web/20120324083116/http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf | archive-date = 24 March 2012 }}{{cite book | vauthors = Reynolds DS | chapter = Chapter 10 Pain Management Companies | chapter-url = https://books.google.com/books?id=3HMoDwAAQBAJ&q=Fulranumab&pg=PA318 |veditors = Allerton C |title=Pain therapeutics: current and future treatment paradigms |date=2013 |publisher=Royal Society of Chemistry |location=Cambridge |isbn=978-1-84973-771-5 |pages=318}}

Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.{{cite web | url = http://www.pmlive.com/pharma_news/j_and_j_drops_ngf_blocker_fulranumab_968433 | title = J&J drops NGF blocker fulranumab | vauthors = Taylor P | date = 4 April 2016 | work = PMLiVE }}